Are you ready to join a team committed to making a meaningful impact on cancer treatment through the discovery and development of precision medicines? At Kura Oncology, you have an opportunity to be a part of something bigger, with a lasting impact that you can be proud of.
At Kura Oncology, we are working to change the paradigm and improve the science of cancer treatment. As an organization, we strive to cultivate a diverse and talented professional culture driven to develop precision medicine therapeutics.
As we continue to build a leading biotech organization with a strong culture, a patient-focused mindset and a team focused on relentless execution, we are looking for innovative, passionate professionals to join us and make our vision a reality.
To succeed at Kura, you will need to have a demonstrated ability for excellence in drug discovery and development and a roll-up your sleeves attitude. The ideal candidate will possess a values-driven work style where integrity and grit drive all behaviors, decisions, and actions.
ESSENTIAL JOB FUNCTIONS:
The Senior Manager / Associate Director, Financial Planning & Analysis (FP&A) will be a key member of the FP&A team, providing operational planning, analytical insights, and strategic financial support to help Kura achieve its commercial, operational, and long-term financial objectives.
This role is responsible for leading core financial planning activities with transparency and rigor, while partnering cross-functionally to provide financial leadership and decision support. The ideal candidate will serve as a trusted advisor to business leaders, translating complex financial data into actionable insights that drive performance and strategic outcomes.
The position supports multiple functional areas and plays a critical role in the annual operating plan, monthly and quarterly forecasting, performance reporting, spend management, investment and program analysis, long-range planning, and continuous improvement of FP&A systems and processes.
- Support and help lead the FP&A function, including long-range planning, annual budgeting, rolling forecasts, and analysis of actual results versus plan.
- Serve as the FP&A business partner for SG&A functions and selected R&D departments, identifying opportunities for efficiency, cost optimization, and process improvement.
- Lead the preparation, analysis, and presentation of financial results, forecasts, and outlooks for supported functions on a quarterly and annual basis.
- Develop a deep understanding of functional operations and resource requirements to effectively challenge assumptions, budgets, and investment requests.
- Provide timely, accurate, and insightful financial analysis and business context to support operating and strategic decision-making.
- Critically review and evaluate annual and multi-year budget submissions; documenting issues, communicating findings, and partnering with stakeholders to resolve concerns.
- Leverage financial systems and tools to analyze and synthesize large data sets into clear, summarized insights for business partners.
- Contribute to ongoing improvements in FP&A processes, reporting, and systems to enhance scalability and decision support.
- Perform other duties as assigned.
JOB QUALIFICATIONS:
- Bachelor’s degree in Finance, Accounting, Economics, or a related field.
- 5+ years of progressive experience in FP&A, corporate finance, or related roles, preferably within a biotech or pharma organization.
- Hands-on experience with budgeting, forecasting, long-range planning, and variance analysis
- Strong planning, reporting and analytical skills with demonstrated business and systems proficiency in previous roles.
- Demonstrated ability to partner effectively with cross-functional stakeholders and support business leaders with financial decision-making.
- Strong proficiency in financial modeling, forecasting, and preparing external presentations; advanced Excel and PowerPoint skills; experience with financial planning software (e.g. Adaptive Insights, Hyperion) a plus
- Highly organized and detail-oriented, with the ability to manage multiple priorities in a fast-paced environment.
The base range for a Senior Manager is $165,000 - $187,000, for an Associate Director the range is $176,000 - $192,000 per year. Individual pay may vary based on additional factors, including, and without limitation, job-related skills, experience, work location, and relevant education or training. Kura's compensation package also includes generous benefits, equity, and participation in an annual target bonus.
#LI-RM1
Kura’s Values that are used for candidate selection and performance assessments:
- We work as one for patients
- We are goal-focused and deliver with excellence
- We are science-driven courageous innovators
- We strive to bring out the best in each other and ourselves
The Kura Package
- Career advancement/ development opportunities
- Competitive comp package
- Bonus
- 401K + Employer contributions
- Generous stock options
- ESPP Plan
- 20 days of PTO to start
- 18 Holidays (Including Summer & Winter Break)
- Generous Benefits Package with a variety of plans available with a substantial employer match
- Paid Paternity/Maternity Leave
- In-Office Catered lunches
- Home Office Setup
- Lifestyle Spending Stipend
- Commuter Stipend (Boston Office)
- Regular employee social activities, including happy hours, monthly birthday celebrations, Kura Koffee Talks, and much more!
Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The Company’s pipeline consists of small molecule drug candidates designed to target cancer signaling pathways. Ziftomenib, a once-daily, oral menin inhibitor, is the first and only investigational therapy to receive Breakthrough Therapy Designation from the U.S. Food and Drug Administration (“FDA”) for the treatment of relapsed/refractory (“R/R”) NPM1-mutant acute myeloid leukemia (“AML”). In November 2024, Kura Oncology entered into a global strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize ziftomenib for AML and other hematologic malignancies. Enrollment in a Phase 2 registration-directed trial of ziftomenib in R/R NPM1-mutant AML has been completed, and in the second quarter of 2025, the companies announced the FDA’s acceptance of a New Drug Application for ziftomenib for the treatment of adult patients with R/R NPM1-mutant AML and assignment of a Prescription Drug User Fee Act target action date of November 30, 2025. Kura Oncology and Kyowa Kirin are also conducting a series of clinical trials to evaluate ziftomenib in combination with current standards of care in newly diagnosed and R/R NPM1-mutant and KMT2A-rearranged AML. KO-2806, a next-generation farnesyl transferase inhibitor, is being evaluated in a Phase 1 dose-escalation trial as a monotherapy and in combination with targeted therapies for patients with various solid tumors. Tipifarnib, a potent and selective farnesyl transferase inhibitor, is currently in a Phase 1/2 trial in combination with alpelisib for patients with PIK3CA-dependent head and neck squamous cell carcinoma. For additional information, please visit Kura’s website at www.kuraoncology.com and follow us on X and LinkedIn.
Kura Oncology is committed to creating a diverse environment and is proud to be an equal opportunity employer. All qualified applicants will receive consideration for employment without regard to race, color, religion, gender, gender identity or expression, sexual orientation, national origin, genetics, disability, age, or veteran status.
If you are a California resident, please see the attached Privacy Notice CA Privacy Notice
Top Skills
What We Do
Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. Our small-molecule drug candidates target signaling pathways and other drivers of cancer where there is a strong scientific and clinical rationale to improve outcomes by identifying those patients most likely to benefit from treatment.
Our pipeline includes tipifarnib, a farnesyl transferase inhibitor, currently in a registration-directed clinical trial and KO-539, a menin-MLL inhibitor, currently in a Phase 1/2A clinical trial.
For additional information, please visit our website at www.kuraoncology.com.
.png)
